Physician profile
Anat Benjamin
NPI 1750371977
$1,575.61
in general payments reported to CMS, 2019-2025
19 companies · $210 in 2025
The $210 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $150 · 2020: $163 · 2021: $355 · 2022: $413 · 2023: $133 · 2024: $152 · 2025: $210.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $495.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $495.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Notal Vision, INC. | $263.31 | 2022 | |
| Allergan, INC. | $235.84 | 2020-2021 | |
| Aerie Pharmaceuticals, INC. | $146.09 | 2019-2020 | |
| Oyster Point Pharma, INC. | $127.59 | 2022-2025 | Tyrvaya, Ryzumvi |
| Biotissue Holdings INC. | $123.34 | 2021-2025 | |
| Tarsus Pharmaceuticals, INC. | $111.17 | 2024-2025 | Xdemvy |
| Bausch & Lomb Americas INC. | $83.86 | 2022-2025 | Vyzulta, Miebo |
| Sun Pharmaceutical Industries INC. | $71.73 | 2022-2024 | Cequa |
| Alcon Vision LLC | $68.20 | 2023-2024 | Simbrinza |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $60.66 | 2019-2020 | |
| Mallinckrodt Hospital Products INC. | $54.51 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $43.47 | 2020-2021 | |
| Eyevance Pharmaceuticals LLC | $41.34 | 2020-2021 | |
| Kala Pharmaceuticals, INC. | $40.28 | 2021 | |
| Dompe US, INC. | $26.32 | 2025 | Oxervate |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $22.01 | 2022 | |
| Harrow Eye, LLC | $19.59 | 2025 | Vevye |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Boston Scientific Corporation | $16.90 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anat Benjamin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.